Nek 2 inhibitors (Huntsman Cancer Institute)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameNek 2 inhibitors (Huntsman Cancer Institute)
Drug Alias NameHCI-2184HCI-2389HCI-2388
ClassificationSmall molecules
Mechanisms of ActionSerine/threonine-protein kinase NEK2 inhibitorsAnticancer protein kinase inhibitors
TargetsSerine/threonine-protein kinase NEK2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHuntsman Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHuntsman Cancer Institute
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A